This site is archived and is no longer updated. It will be taken offline in mid-July. All the latest AWMSG recommendations, guidance and information is available on our new website at:
awmsg logo

elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (Genvoya®)

Reference No. 3628

Publication date:

Appraisal information

elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (Genvoya®) 150 mg/150 mg/200 mg/10 mg film-coated tablet

Company: Gilead Sciences Ltd
BNF category: Infections
NMG meeting date: Not scheduled
AWMSG meeting date: Not scheduled
Submission Type: Nonsubmission
Status: Not endorsed
Advice No: Not available
Ratification by Welsh Government: 22/03/2018

Current Progress

Ratification by
Welsh Government

AWMSG advice

In the absence of a submission from the holder of the marketing authorisation, elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (Genvoya®) cannot be endorsed for use within NHS Wales for the treatment of human immunodeficiency virus-1 (HIV-1) infection without any known mutations associated with resistance to the integrase inhibitor class, emtricitabine or tenofovir, in children aged from 6 years to 12 years and with body weight at least 25 kg for whom alternative regimens are unsuitable due to resistance or toxicities.
Statement of Advice (SOA)